abstract |
The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the activity of the CXCL12/CXCR4 pathway, and/or the activity of the IGF1R pathway. Provided herein are also combination therapy of cancer treatment using FTI and either an IGF1R inhibitor or a CXCR4 antagonist. |